Photo A bottle of vaccine for the new coronavirus infection developed by Pfizer (Reuters = joint)
US vaccination December 12th, administration adviser "Original life in May"
If you write the contents roughly
He also pointed out that vaccination will become widespread and many people will gain immunity, making it difficult for the infection to spread.
[Washington joint] Mr. Sulaui, who is an adviser to the development plan of the new coronavirus infectious disease vaccine under the Trump administration ... → Continue reading
We will deliver the latest news in Japan and abroad in a precise and prompt manner.
Wikipedia related words
If there is no explanation, there is no corresponding item on Wikipedia.
Collective immunity(Sudden Meneki,British: herd immunity, herd effect, community immunity, population immunity, social immunity) IsInfectionTo the majority ofImmunologyIt is an indirect protective effect that occurs when you have, and is a means to protect people who are not immune.. In a population where a large number of people are immune, it is likely that the chain of infection will be broken, and the spread of the disease will be subdued or moderate... The higher the proportion of people with immunity in a community, the less likely non-immune people will be in contact with infected people..
Personal immunity is the recovery from infectious diseases andvaccinationEarned by.. Some people are unable to acquire immunity for medical reasons and collective immunity is an important safeguard against these people.. When the proportion of people with immunity reaches a certain value, collective immunity will gradually eliminate the disease from the population.. If this elimination is achieved worldwide, the number of infections could be permanently reduced to zero, a condition called eradication or eradication... By this techniquesmallpoxWas eradicated in 1977 and other infectious diseases are being locally excluded... Collective immunity does not apply to all infectious diseases,Contagion, That is, only applicable to diseases that are transmitted from one person to another. For example,tetanusIs an infectious disease but is not contagious, so collective immunity is not applied.
Many children in the 1930smeaslesIt was observed that the immunity against P. aureus temporarily reduced the number of new infections among nonimmunized children, which was recognized as a naturally occurring phenomenon... AW HedrichBaltimoreOf measles inEpidemiologyAnd noted that after many children acquired immunity to measles, the number of new infections also temporarily decreased among susceptible children... Despite this finding, efforts to control and eliminate measles were discovered in the 1960s.Measles vaccineDid not succeed until mass vaccination of.
After that, induction of collective immunity by vaccination became common, and successful prevention of spread in many infectious diseases... Mass immunization, discussions on eradication of disease, and cost-benefit analysis of immunization have made "population immunity" widely used... In the 1970s, the theorem used to calculate the population immune threshold was developed.. From the 1960s to the 1970ssmallpoxIn the eradication movement,OutbreakImmunize everyone around the infected to prevent spread(Ring vaccination).
However, with the general availability of mass vaccination and siege immunization, the complexities and difficulties of mass immunity have emerged. The modeling of the spread of infectious diseases initially made many non-existent assumptions that the entire population was susceptible and mixed well, so more accurate models are being developed..
In recent years, there is a theory that dominant strains of microorganisms may change due to collective immunity, which means that collective immunity acts as a selective pressure against microorganisms, or that collective immunity against one strain causes expansion of other existing strains. To bring.
But even now,Vaccine evasionThere is a campaign against vaccination, etc., which is a problem of collective immunity.. Especially in societies/communities where the vaccination rate is insufficient, collective immunity has declined or disappeared, and preventable diseases persist and reoccur..
In Japan as well, there were cases of illness, disability, or death due to side effects of vaccination, and lawsuits began in 47 ()... Also in 2016Cervical cancer vaccine(Human papillomavirus vaccine) There was also a lawsuit regarding side reactions after vaccination (pending as of March 2020).WHOIn a statement by the Global Advisory Committee on Vaccine safety (GACVS) of Vaccine Safety, in the name of only Japan issuing a recommendation to discontinue cervical cancer vaccination,
The expert side reaction review committeeCervical cancer vaccineDespite the conclusion that there is no causal relationship between政府He is unable to resume vaccination. As GASVS has pointed out,evidenceBased political decisions are safe and effectivevaccineIt hinders the inoculation and causes real damage. A young woman should be avoidedCervical cancerContinue to be exposed to the damage and threat of. — World Health Organization International Commission on Vaccine Safety, December 2015, 12
Protection of non-immune people
Some people may not be immunized after vaccination or may not be vaccinated for medical reasons.. Also, newborns lose safety reasons and vaccine effects.Passive immunityCannot receive many vaccines due to the presence of.HIV / AIDS,Lymphoma,leukemia,Bone marrow Ofcancer,spleenDysfunction,chemical treatment,Radiation therapyPeople who are immunocompromised due to, for example, may have lost their previous immunity, and the vaccine may not be useful due to immunodeficiency... Vaccines are generally not perfect, and the immune system of some people may not elicit long-term immunity due to an adequate immune response to the vaccine. Therefore, even those who have been vaccinated may have lost their immunity... Also, for vaccinesTabooMay exist, which may prevent certain people from getting immunity.. These people not only have immunity, but also because of their healthcomplicationsRisk of developing illness is high, but protection may be available if a sufficient proportion of people in the population are immune.
If a high level of immunity is acquired in one age group, it can form a group immunity to other age groups..Social Services LizardVaccination of adults reduces the number of newborns at the highest risk of complications.. This is especially important because most newborn transmissions come from familiar families..
Streptococcus pneumoniaeRotavirusVaccination against vaccination has been shown to reduce hospitalizations due to pneumococcal and rotavirus infections in older children and adults who are not usually vaccinated with these vaccines.
influenzaTend to be more severe in the older population than in the younger population, but in this population the effects of the influenza vaccine are lost due to age-related weakening of the immune system. But,Seasonal fluIt has been shown that prioritizing vaccination of school-aged children with children will provide some degree of protection even to the elderly..
Sexually transmitted diseaseAs for, the high level of immunity in one sex leads to a collective immunity in both sexes.. For sexually transmitted disease vaccines targeting one sex, if the vaccination rate for the target sex is high, sexually transmitted diseases will be significantly reduced in both sexes... However, the effect of collective immunity by vaccination against womenHomosexualOf men.. If the vaccination rate of the target sex is low, it is necessary to immunize other sex to obtain sufficient protective effect.. Compromising sexually transmitted diseases is high-risk sexual behavior. The majority of infections occur in people at moderate risk, while the majority of transmissions to others result from people performing high-risk sexual behavior... For these reasons, immunization of high-risk individuals of both sexes is necessary to establish collective immunity.
Impact on virus evolution
Collective immunity is itself against a particular virusAnd influence the evolution of the virus. In this case, the emergence of new strains called escape mutants that can bypass population immunity and expand more easily.. At the molecular level, the surface of the virusantigen(Generally viralCapsidProtein)genomeIn the areaMutationAccumulatedEpitopeChanges,Antigen driftA change called.. In addition,ReassemblyChanges caused by newSerotypeMay be produced,Antigen shiftCalled. This is more likely to happen when multiple stocks are in circulation.. When such changes occurMemory T cellsCan no longer recognize the virus, leaving people immune to the dominant strain.. With the fluNorovirusIn both cases, the epidemic is a continuous wave, as the epidemic temporarily induces collective immunity until a new dominant strain emerges... The evolution of this virus has become a challenge for population immunity, and the development of broadly neutralizing antibodies and "universal vaccines" (universal vaccines) that are not limited to the effects on specific serotypes is currently under way. Have been.
Because of the high level of immunity to a serotype,PrevalenceDecrease, and other serotypes increase in lieu of it, a phenomenon called serotype replacement or serotype shifting may occur.. Streptococcus pneumoniaeStreptococcus pneumoniaeAn early vaccine againstDrug resistanceIncluding the type of serotype included in the vaccineNasopharynxSignificantly reduced carriage, but the reduction was completely offset by increased carriage of non-vaccine serotypes.. However, serotypes not included in the vaccine were less invasive than serotypes included in the vaccine, so the incidence of disease did not increase proportionately.. It is also effective against newly emerging serotypesPneumococcal vaccineWas introduced, and it became possible to counter the increase.. Despite the potential for further shifts in the future, strategies to address them include expansion of the serotypes in the vaccine, whole-cell inactivated vaccines containing more surface antigens, or multiple serotypes. Development of vaccines targeting proteins present in.
Eradication of disease
If collective immunity is established and maintained in a population for a sufficient period of time, the disease will be eliminated and transmission will not spread.. Eradication of the disease is declared when elimination of the disease is achieved around the world and the number of occurrences is permanently reduced to zero.. Eradication of disease controls the spread of infectious diseasespublic healthCan be considered the ultimate impact or result of.. Eradication of illness can eliminate morbidity and mortality, save money for individuals, health care providers, and governments, and use the resources used to control illness for other things There are advantages such as being able to.
NowPolioEfforts have been made to eradicate the disease by means of group immunity, but public anxiety and distrust of modern medicine make eradication difficult... Compulsory vaccination may also be useful in eradication efforts if not enough people are willing to be vaccinated.
Free ride to collective immunity (free rider)
Collective immunityFree riderVulnerable to problems.. Those who are not immune, especially those who choose not to be vaccinated, will be free to ride on the collective immunity created by those who are immune... As the number of free riders in the population increases, preventable diseasesOutbreakAre more likely to occur and become more serious due to loss of collective immunity.. The reason for choosing a free ride is the lack of perceptual effectivenessThink that the risk of vaccine is greater than the risk of infectionDistrust of vaccines and public health authorities,Band wagon effect,Collective thinking, Social norms andTuning pressure, Religious beliefsAnd so on. If the vaccination rate is high enough, you are more likely to take a free ride, believing that you don't need to be immune, as others are already immune enough..
|Social Services Lizard||Splash infection||12-17||92-94%|
|Polio||Fecal mouth infection|
|New coronavirus infection|
(Global pandemic of new coronavirus infections)
(West Africa Ebola outbreak in 2014)
People who are immune to the disease act as a barrier to the spread of the disease, reducing or preventing transmission to others... Personal immunity is acquired by artificial means such as natural infection and vaccination..When the proportion of people with immunity reaches a critical ratio called the herd immunity threshold (HIT) or herd immunity level (HIL), the disease is no longer maintained within the population and the spread of the disease ends. To do.. This threshold isBasic reproduction number R0 Can be calculated fromR0Is the average number of new infections from individual cases in a homogenous, well-mixed population, a fully susceptible population with contact by all.. The proportion of people in a population who are susceptible to infection S Then,
At that point, the transmission is in a steady state.S Is the percentage of people with immunity p Using (1 − p) Can be rewritten as Then, the above equation is transformed as follows.
p Is transformed so that is on the left side of the equation, and pc The value written as is the critical ratio necessary to stop the spread of disease transmission within the population, or the population immune threshold (HIT).R0Acts as an indicator of contagiousness,R0The lower the value, the lower the HIT, whileR0The higher the value, the higher the HIT. For example,R0Is 2, the HIT is theoretically only 50%, butR0HIT is 10% when is 90..These calculations assume that the population is completely sensitive, that is, no one is immune to the disease.In reality, immunized people are present in different proportions within the population at any time of any illness... To take this into consideration, the effective number of reproductions Re(Effective reproductive number,Rt Is also used) t The proportion of susceptible populations inR0By taking the time t An average number of infections caused byReIf is maintained below 1, the number of cases within the population gradually decreases and the disease is eliminated..When the proportion of people immunized against the disease in a population exceeds HIT, the number of cases decreases faster, outbreaks are less likely to occur, and if they do occur, they are smaller..ReIs greater than 1 sickThe number of occurrencesIs no longer seen, and the disease is actively spreading throughout the population, causing more than normal infections.
There is a second assumption in these calculations that the population is homogeneous and well mixed, that is, all people in the population make contact, but the model of the real population has a limited number of people. Make relatively close contact with othersSocial networkIs more appropriate.In such networks, transmission occurs only between people who are geographically and physically close to each other... Disease HIT changes depending on the shape and size of the network, and the number of occurrences is likely to increase or decrease.. In a non-homogeneous population,R0Is considered an indicator of the number of cases caused by an infectious "typical" person, the value of which will depend on how individuals interact within the network... Disease transmission can occur more easily in highly connected networks,R0And HIT will be higher than less connected networks.
The main ways to increase the level of immunity in a population are:vaccinationIs.. The concept of vaccination isVacciniaBased on the observation that dairy farmers affected by smallpox are immune to smallpox and started as vaccination with cowpox virus to prevent smallpox.. Well-developed vaccines provide protection in a much safer way than natural infections. Vaccines generally do not cause the disease they seek to protect andSide effectsIs much less common than natural infection complications.Immune systemImmunity induced by vaccination is similar to the immunity induced during the course of illness and recovery, as it does not distinguish between natural infection and vaccine and forms active immunity against both.. Vaccine manufacturers aim to produce vaccines with a low failure rate (the rate at which immunity is not induced or attenuated) and policy makers aim to recommend their use in order to achieve collective immunity by vaccination... With the successful introduction and widespread use of vaccines, we observe a sharp decrease in the number of diseases protected by the vaccine, which inevitably reduces the number of hospitalizations and deaths due to the disease..
Assuming the effectiveness of the vaccine is 100%, the formula for calculating the population immunity threshold is the level of vaccination required to eliminate the disease. Vc Can also be used to calculate.. However, the effectiveness of vaccines is often not perfect, so E(Effectiveness) has to be taken into account,VcIs as follows:
E Is (1 − 1/R0), it is impossible to eliminate the disease even if the population is fully vaccinated.. Similarly, vaccine-induced immunity can be attenuated, as seen with acellular pertussis vaccines, and thus higher levels of levels are needed to maintain collective immunity.Boosteris necessary.. Once the epidemic of the disease in the population is over, vaccination is the only way to contribute to this reduction, as natural infections no longer reduce the susceptibility rate in the population.. The relationship between the prevalence rate, vaccination rate, and efficacy rate is based on E And the proportion of people who have been vaccinated in the group pv Is the product of.
Increasing vaccination coverage or vaccine efficacy further reduces disease incidence.. The reduction rate of the number of cases is sickR0Depends onR0The smaller the value of, the sharper the decrease... Vaccines usually have at least one medical contraindication to a particular population. However, if the vaccine's effectiveness and coverage are high enough, such people can be protected by collective immunity... Vaccine effectiveness is often but not alwaysPassive immunityIs reduced by.. As a result, boosters are recommended for some vaccines and others may not be given until passive immunity disappears..
Vaccination programCost-benefit analysisOften, collective immunity is taken into account when performing. Positive due to high level of immunityExternalityAre considered to occur and produce additional benefits from reduced disease that do not appear if collective immunity is not formed within the population... Therefore, incorporating population immunity into the cost-benefit analysis will result in a better cost-benefit ratio and an increase in the number of cases prevented by vaccination... Studies designed to assess the benefits of collective immunity include recording the number of outbreaks in households where members were vaccinated, randomized comparisons of populations in vaccinated and unvaccinated areas, The number of outbreaks before and after the introduction of the vaccination program is being observed... From these, it was observed that the number of outbreaks may decrease beyond the level expected from only the direct protective effect, suggesting that population immunity contributes to the decrease... If serotype replacement is taken into account, the benefits expected from vaccination are reduced.
Personal immunity to pathogensantibodyIt is also acquired passively by moving from a person with to another person. As a natural phenomenon, there are migration antibodies, mainlyIgGAntibodyplacenta,colostrumThroughFetusAnd transition to newborns.. It can also be done artificially, so thatserum,plasmaOf passive immunity is achieved by injecting sucrose into susceptible individuals.. The protective effect of passive immunity is immediately exerted, but its contribution to collective immunity is temporary because it attenuates in a few weeks to several months... With regard to diseases such as influenza and tetanus, where the fetus and newborn are particularly severe, pregnant women may obtain immunity with the aim of transferring antibodies to the child... Similarly, antibodies may be prepared to prevent infection or reduce symptoms in high-risk populations who are more likely to be infected or are more likely to develop complications..
- ^ a b c d e f g h i j k l m n o p q r Fine, P .; Eames, K .; Heymann, DL (1 April 2011). “'Herd immunity': A rough guide”. Clinical Infectious Diseases 52 (7): 911–16. two:10.1093 / cid / cir007. PMID 21427399.
- ^ Gordis, L. (14 November 2013). E. Elsevier Health Sciences. Pp. 26–27. ISBN 978-1455742516 2015/3/29Browse.
- ^ a b c d Merrill, RM (2013). Introduction to Epidemiology. Jones & Bartlett Publishers. Pp. 68–71. ISBN 978-1449645175 2015/3/29Browse.
- ^ a b c d e "Herd Immunity”. Oxford Vaccine Group, University of Oxford. 2017/12/12Browse.
- ^ a b c d e f Somerville, M .; Kumaran, K .; Anderson, R. (19 January 2012). Public Health and Epidemiology at a Glance. John Wiley & Sons. Pp. 58–59. ISBN 978-1118308646 2015/3/29Browse.
- ^ a b c d Cliff, A .; Smallman-Raynor, M. (11 April 2013). Oxford Textbook of Infectious Disease Control: A Geographical Analysis from Medieval Quarantine to Global Eradication. Oxford University Press. Pp. 125–36. ISBN 978-0199596614 2015/3/29Browse.
- ^ a b c d e f g Kim, TH; Jonhstone, J .; Loeb, M. (September 2011). “Vaccine herd effect”. Scandinavian Journal of Infectious Diseases 43 (9): 683–89. two:10.3109/00365548.2011.582247. PMC: 3171704. PMID 21604922.
- ^ Topley, WWC; Wilson, GS (May 1923). “The Spread of Bacterial Infection. The Problem of Herd-Immunity”. The Journal of Hygiene 21 (3): 243–249. two:10.1017 / s0022172400031478. PMC: 2167341. PMID 20474777.
- ^ a b c * Hinman, AR; Orenstein, WA; Papania, MJ (1 May 2004). “Evolution of measles elimination strategies in the United States”. The Journal of Infectious Diseases 189 (Suppl 1): S17–22. two:10.1086/377694. PMID 15106084.
*Sencer, DJ; Dull, HB; Langmuir, AD (March 1967). “Epidemiologic basis for eradication of measles in 1967”. Public Health Reports 82 (3): 253–56. two:10.2307/4592985. JSTOR 4592985. PMC: 1919891. PMID 4960501.
- ^ a b c d e f g h i j k l m Garnett, GP (1 February 2005). “Role of Herd Immunity in Determining the Effect of Vaccines against Sexually Transmitted Disease”. The Journal of Infectious Diseases 191 (Suppl 1): S97–106. two:10.1086/425271. PMID 15627236.
- ^ Strassburg, MA (1982). “The global eradication of smallpox”. American Journal of Infection Control 10 (2): 53–59. two:10.1016 / 0196-6553 (82) 90003-7. PMID 7044193.
- ^ a b c Bull, RA; White, PA (2011). “Mechanisms of GII.4 norovirus evolution”. Trends in Microbiology 19 (5): 233–40. two:10.1016 / j.tim.2011.01.002. PMID 21310617.
- ^ a b c McEllistrem, MC; Nahm, MH (2012). “Novel pneumococcal serotypes 6C and 6D: Anomaly or harbinger”. Clinical Infectious Diseases 55 (10): 1379–86. two:10.1093 / cid / cis691. PMC: 3478140. PMID 22903767.
- ^ a b c Quadri-Sheriff, M .; Hendrix, KS; Downs, SM; Sturm, LA; Zimet, GD; Finnell, SM (September 2012). “The role of herd immunity in parents' decision to vaccinate children: a systematic review”. Pediatrics 130 (3): 522–30. two:10.1542 / peds.2012-0140. PMID 22926181.
- ^ a b c d e Dubé, E .; Laberge, C .; Guay, M .; Bramadat, P .; Roy, R .; Bettinger, J. (August 2013). “Vaccine hesitancy: an overview”. Human Vaccines & Immunotherapeutics 9 (8): 1763–73. two:10.4161 / hv.24657. PMC: 3906279. PMID 23584253.
- ^ a b c d Ropeik, D. (August 2013). “How society should respond to the risk of vaccine rejection”. Human Vaccines & Immunotherapeutics 9 (8): 1815–18. two:10.4161 / hv.25250. PMC: 3906287. PMID 23807359.
- ^ Vaccination vaccination incident
- ^ Lack of "information" and "system" revealed in the "Cervical Cancer Vaccine Litigation" I do not think it is effective in solving the cervical cancer vaccine lawsuit.Apr 2016, 04 08:06 JST | Update Apr 53, 2017 04:07 JS
- ^ GACVS 2015.
- ^ Kariko Mikiko Cervical Cancer Vaccine, WHO Reiterates Safety Statement-Refers to Japan's Situation, "Causes Real Damage" Medical Care CB News December 2015, 12
- ^ "GACVS found no evidence to suggest a causal link with the HPV vaccine": Global Advisory Committee on Vaccine Safety (2014-03-12) (pdf). Statement on the continued safety of HPV vaccination (Report) 2018/3/10Browse..
- ^ "The case for vaccination". North & South. Bauer Media. 2015/7/3Browse.
- ^ a b c d Cesaro, S .; Giacchino, M .; Fioredda, F .; Barone, A .; Battisti, L .; Bezzio, S .; Frenos, S .; De Santis, R .; Livadiotti, S .; Marinello, S. Zanazzo, AG; Caselli, D. (2014). “Guidelines on vaccinations in paediatric haematology and oncology patients”. Biomed Res. Int. 2014: 707691. two:10.1155/2014/707691. PMC: 4020520. PMID 24868544.
- ^ a b c Munoz, FM (2013). “Maternal immunization: An update for pediatricians”. Pediatric Annals 42 (8): 153–58. two:10.3928 / 00904481-20130723-09. PMID 23910028.
- ^ a b c National Center for Immunization and Respiratory Diseases (2011). “General recommendations on immunization – recommendations of the Advisory Committee on Immunization Practices (ACIP)”. MMWR. Recommendations and Reports: Morbidity and Mortality Weekly Report. Recommendations and Reports / Centers for Disease Control 60 (2): 1–64. PMID 21293327.
- ^ a b Wolfe, RM (2012). “Update on adult immunizations”. The Journal of the American Board of Family Medicine 25 (4): 496–510. two:10.3122 / jabfm.2012.04.100274. PMID 22773718.
- ^ Esposito, S; Bosis, S; Morlacchi, L; Baggi, E; Sabatini, C; Principi, N (2012). “Can infants be protected by means of maternal vaccination?”. Clinical Microbiology and Infection 18 Suppl 5: 85–92. two:10.1111 / j.1469-0691.2012.03936.x. PMID 22862749.
- ^ a b c Rakel, D .; Rakel, RE (2015). Textbook of Family Medicine. Elsevier Health Sciences. Pp. 99, 187. ISBN 978-0323313087 2015/3/30Browse.
- ^ a b c Tulchinsky, TH; Varavikova, EA (26 March 2014). The New Public Health: An Introduction for the 21st Century.Academic Press. Pp. 163–82. ISBN 978-0124157675 2015/3/30Browse.
- ^ a b McGirr, A; Fisman, DN (2015). “Duration of Pertussis Immunity After DTaP Immunization: A Meta-analysis”. Pediatrics 135 (2): 331–43. two:10.1542 / peds.2014-1729. PMID 25560446.
- ^ Zepp, F; Heininger, U; Mertsola, J; Bernatowska, E; Guiso, N; Roord, J; Tozzi, AE; Van Damme, P (2011). “Rationale for pertussis booster vaccination throughout life in Europe”. The Lancet Infectious Diseases 11 (7): 557–70. two:10.1016 / S1473-3099 (11) 70007-X. PMID 21600850.
- ^ a b c d e Pittet, LF; Posfay-Barbe, KM (2012). “Pneumococcal vaccines for children: A global public health priority”. Clinical Microbiology and Infection 18 Suppl 5: 25–36. two:10.1111 / j.1469-0691.2012.03938.x. PMID 22862432.
- ^ Nakagomi, O; Iturriza-Gomara, M; Nakagomi, T; Cunliffe, NA (2013). “Incorporation of a rotavirus vaccine into the national immunisation schedule in the United Kingdom: A review”. Expert Opinion on Biological Therapy 13 (11): 1613–21. two:10.1517/14712598.2013.840285. PMID 24088009.
- ^ Lopman, BA; Payne, DC; Tate, JE; Patel, MM; Cortese, MM; Parashar, UD (2012). “Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011”. Current Opinion in Virology 2 (4): 434–42. two:10.1016 / j.coviro.2012.05.002. PMID 22749491.
- ^ a b Kim, TH (2014). “Seasonal influenza and vaccine herd effect”. Clinical and Experimental Vaccine Research 3 (2): 128–32. two:10.7774 / cevr.2014.3.2.128. PMC: 4083064. PMID 25003085.
- ^ a b c Lowy, DR; Schiller, JT (2012). “Reducing HPV-associated cancer globally”. Cancer Prevention Research 5 (1): 18–23. two:10.1158 / 1940-6207.CAPR-11-0542. PMC: 3285475. PMID 22219162.
- ^ a b c d e Lenzi, A; Mirone, V; Gentile, V; Bartoletti, R; Ficarra, V; Foresta, C; Mariani, L; Mazzoli, S et al. (2013). “Rome Consensus Conference – statement; human papilloma virus diseases in males”. BMC Public Health 13: 117. two:10.1186 / 1471-2458-13-117. PMC: 3642007. PMID 23391351.
- ^ Garland, SM; Skinner, SR; Brotherton, JM (2011). “Adolescent and young adult HPV vaccination in Australia: Achievements and challenges”. Preventive Medicine 53 Suppl 1: S29–35. two:10.1016 / j.ypmed.2011.08.015. PMID 21962468.
- ^ a b c d e f g h Rodpothong, P; Auewarakul, P (2012). “Viral evolution and transmission effectiveness”. World Journal of Virology 1 (5): 131–34. two:10.5501 / wjv.v1.i5.131. PMC: 3782273. PMID 24175217.
- ^ a b Corti, D; Lanzavecchia, A (2013). “Broadly neutralizing antiviral antibodies”. Annual Review of Immunology 31: 705–42. two:10.1146 / annurev-immunol-032712-095916. PMID 23330954.
- ^ a b Ramani, S; Atmar, RL; Estes, MK (2014). “Epidemiology of human noroviruses and updates on vaccine development”. Current Opinion in Gastroenterology 30 (1): 25–33. two:10.1097 / MOG.0000000000000022. PMC: 3955997. PMID 24232370.
- ^ a b c Pleschka, S (2013). “Overview of Influenza Viruses”. Swine Influenza. Current Topics in Microbiology and Immunology. 370. pp. 1–20. two:10.1007 / 82_2012_272. ISBN 978-3642368707. PMID 23124938
- ^ Reperant, LA; Rimmelzwaan, GF; Osterhaus, AD (2014). “Advances in influenza vaccination”. F1000 Prime Reports 6: 47. two:10.12703 / p6-47. PMC: 4047948. PMID 24991424.
- ^ Han, T; Marasco, WA (2011). “Structural basis of influenza virus neutralization”. Annals of the New York Academy of Sciences 1217: 178–90. two:10.1111 / j.1749-6632.2010.05829.x. PMC: 3062959. PMID 21251008.
- ^ a b c Weinberger, DM; Malley, R; Lipsitch, M (2011). “Serotype replacement in disease after pneumococcal vaccination”. The Lancet 378 (9807): 1962–73. two:10.1016 / S0140-6736 (10) 62225-8. PMC: 3256741. PMID 21492929.
- ^ Dagan, R (2009). “Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae”. Clinical Microbiology and Infection 15 Suppl 3: 16–20. two:10.1111 / j.1469-0691.2009.02726.x. PMID 19366365.
- ^ Lynch Jp, 3rd; Zhanel, GG (2010). “Streptococcus pneumoniae: Epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines”. Current Opinion in Pulmonary Medicine 16 (3): 217–25. two:10.1097 / MCP.0b013e3283385653. PMID 20375783.
- ^ Njeumi, F; Taylor, W; Diallo, A; Miyagishima, K; Pastoret, PP; Vallat, B; Traore, M (2012). “The long journey: A brief review of the eradication of rinderpest”. Revue Scientifique et Technique (International Office of Epizootics) 31 (3): 729–46. PMID 23520729.
- ^ a b Smith, KA (2013). “Smallpox: Can we still learn from the journey to eradication?”. The Indian Journal of Medical Research 137 (5): 895–99. PMC: 3734679. PMID 23760373.
- ^ a b c d e Perisic, A; Bauch, CT (2009). “Social contact networks and disease eradicability under voluntary vaccination”. PLoS Computational Biology 5 (2): e1000280. two:10.1371 / journal.pcbi.1000280. PMC: 2625434. PMID 19197342.
- ^ a b c d e f Fu, F; Rosenbloom, DI; Wang, L; Nowak, MA (2011). “Imitation dynamics of vaccination behavior on social networks”. Proceedings of the Royal Society B: Biological Sciences 278 (1702): 42–49. two:10.1098 / rspb.2010.1107. PMC: 2992723. PMID 20667876.
- ^ Wicker, S; Maltezou, HC (2014). “Vaccine-preventable diseases in Europe: Where do we stand?”. Expert Review of Vaccines 13 (8): 979–87. two:10.1586/14760584.2014.933077. PMID 24958075.
- ^ a b c Fukuda, E .; Tanimoto, J. (2014). Impact of Stubborn Individuals on a Spread of Infectious Disease under Voluntary Vaccination Policy. Springer. Pp. 1–10. ISBN 978-3319133591 2015/3/30Browse.
- ^ a b Barrett, Scott (2014). “Global Public Goods and International Development”. In J. Warren Evans, Robin Davies. Too Global To Fail: The World Bank at the Intersection of National and Global Public Policy in 2025. World Bank Publications. Pp. 13–18. ISBN 978-1464803109
- ^ a b c Gowda, C; Dempsey, AF (2013). “The rise (and fall?) Of parental vaccine hesitancy”. Human Vaccines & Immunotherapeutics 9 (8): 1755–62. two:10.4161 / hv.25085. PMC: 3906278. PMID 23744504.
- ^ Ozawa, S; Stack, ML (2013). “Public trust and vaccine acceptance – international perspectives”. Human Vaccines & Immunotherapeutics 9 (8): 1774–78. two:10.4161 / hv.24961. PMC: 3906280. PMID 23733039.
- ^ Parker, AM; Vardavas, R; Marcum, CS; Gidengil, CA (2013). “Conscious consideration of herd immunity in influenza vaccination decisions”. American Journal of Preventive Medicine 45 (1): 118–21. two:10.1016 / j.amepre.2013.02.016. PMC: 3694502. PMID 23790997.
- ^ Unless noted, R0 values are from: History and Epidemiology of Global Smallpox Eradication Archived 2017-03-17 at the Wayback Machine. From the training course titled "Smallpox: Disease, Prevention, and Intervention". The Centers for Disease Control and Prevention and the World Health OrganizationSlide 17. Retrieved 13 March 2015.
- ^ a b Biggerstaff, M; Cauchemez, S; Reed, C; Gambhir, M; Finelli, L (2014). “Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: A systematic review of the literature”. BMC Infectious Diseases 14: 480. two:10.1186 / 1471-2334-14-480. PMC: 4169819. PMID 25186370.
- ^ “COVID-19 herd immunity: where are we?”. Nature Reviews. Immunology 20 (10): 583–584. (October 2020). two:10.1038 / s41577-020-00451-5. PMC: 7480627. PMID 32908300.
- ^ “Herd Immunity: Understanding COVID-19”. Immunity 52 (5): 737–741. (May 2020). two:10.1016 / j.immuni.2020.04.012. PMC: 7236739. PMID 32433946.
- ^ Wallinga, J; Teunis, P (2004). “Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures”. American Journal of Epidemiology 160 (6): 509–16. two:10.1093 / aje / kwh255. PMID 15353409.
- ^ Althaus, CL (2014). “Estimating the Reproduction Number of Ebola Virus (EBOV) During the 2014 Outbreak in West Africa”. PLoS Currents 6. two:10.1371 / currents.outbreaks.91afb5e0f279e7f29e7056095255b288. PMC: 4169395. PMID 25642364.
- ^ a b Dabbaghian, V .; Mago, VK (27 October 2013). Theories and Simulations of Complex Social Systems. Springer. Pp. 134–35. ISBN 978-3642391491 2015/3/29Browse.
- ^ a b Rashid, H; Khandaker, G; Booy, R (2012). “Vaccination and herd immunity: What more do we know?”. Current Opinion in Infectious Diseases 25 (3): 243–49. two:10.1097 / QCO.0b013e328352f727. PMID 22561998.
- ^ Maglione, MA; Das, L; Raaen, L; Smith, A; Chari, R; Newberry, S; Shanman, R; Perry, T et al. (2014). “Safety of vaccines used for routine immunization of US Children: A systematic review”. Pediatrics 134 (2): 325–37. two:10.1542 / peds.2014-1079. PMID 25086160.
- ^ Demicheli, V; Rivetti, A; Debalini, MG; Di Pietrantonj, C (2012). “Vaccines for measles, mumps and rubella in children”. Cochrane Database of Systematic Reviews. 2. CD004407. two:10.1002 / 14651858.CD004407.pub3. PMC: 6458016. PMID 22336803
- ^ a b c Pommerville, JC (2 December 2014). Fundamentals of Microbiology: Body Systems Edition. Jones & Bartlett Publishers. Pp. 559–63. ISBN 978-1284057102 2015/3/30Browse.
- ^ Papaloukas, O; Giannouli, G; Papaevangelou, V (2014). “Successes and challenges in varicella vaccine”. Therapeutic Advances in Vaccines 2 (2): 39–55. two:10.1177/2051013613515621. PMC: 3991154. PMID 24757524.
- ^ Shann, F (2013). “Nonspecific effects of vaccines and the reduction of mortality in children”. Clinical Therapeutics 35 (2): 109–14. two:10.1016 / j.clinthera.2013.01.007. PMID 23375475.
- ^ Visser, A; Hoosen, A (2012). “Haemophilus influenzae type b conjugate vaccines --a South African perspective”. Vaccine 30 Suppl 3: C52–57. two:10.1016 / j.vaccine.2012.06.022. PMID 22939022.
- ^ Leuridan, E; Sabbe, M; Van Damme, P (2012). “Measles outbreak in Europe: Susceptibility of infants too young to be immunized”. Vaccine 30 (41): 5905–13. two:10.1016 / j.vaccine.2012.07.035. PMID 22841972.
- ^ Hodgins, DC; Shewen, PE (2012). “Vaccination of neonates: Problem and issues”. Vaccine 30 (9): 1541–59. two:10.1016 / j.vaccine.2011.12.047. PMID 22189699.
- ^ Bärnighausen, T .; Bloom, DE; Cafiero-Fonseca, ET; O'Brien, JC (26 August 2014). “Valuing vaccination”. Proc Natl Acad Ski USA 111 (34): 12313–19. two:10.1073 / pnas.1400475111. PMC: 4151736. PMID 25136129.
- ^ a b c Deogaonkar, R .; Hutubessy, R .; van der Putten I .; Evers S .; Jit M. (16 October 2012). “Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries”. BMC Public Health 12: 878. two:10.1186 / 1471-2458-12-878. PMC: 3532196. PMID 23072714.
- ^ a b Jit, M .; Newall, AT; Beutels, P. (April 2013). “Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies”. Hum Vaccin Immunother 9 (4): 834–40. two:10.4161 / hv.23637. PMC: 3903903. PMID 23357859.
- ^ Chucri, TM; Monteiro, JM; Lima, AR; Salvadori, ML; Kfoury Jr, JR; Miglino, MA (2010). “A review of immune transfer by the placenta”. Journal of Reproductive Immunology 87 (1–2): 14–20. two:10.1016 / j.jri.2010.08.062. PMID 20956021.
- ^ Palmeira, P; Quinello, C; Silveira-Lessa, AL; Zago, CA; Carneiro-Sampaio, M (2012). “IgG placental transfer in healthy and pathological pregnancies”. Clinical and Developmental Immunology 2012: 1–13. two:10.1155/2012/985646. PMC: 3251916. PMID 22235228.
- ^ a b Parija, SC (10 February 2014). Textbook of Microbiology & Immunology. Elsevier Health Sciences. Pp. 88–89. ISBN 978-8131236246 2015/3/30Browse.
- ^ Detels, R .; Gulliford, M .; Karim, QA; Tan, CC (1 February 2015). Oxford Textbook of Global Public HealthOxford University Press. P. 1490. ISBN 978-0199661756 2015/3/30Browse.
- ^ Demicheli, Vittorio; Barale, Antonella; Rivetti, Alessandro (2015-07-06). “Vaccines for women for preventing neonatal tetanus”. The Cochrane Database of Systematic Reviews (7): CD002959. two:10.1002 / 14651858.CD002959.pub4. ISSN 1469-493X. PMID 26144877.
- ^ Swamy, GK; Garcia-Putnam, R (2013). “Vaccine-preventable diseases in pregnancy”. American Journal of Perinatology 30 (2): 89–97. two:10.1055 / s-0032-1331032. PMID 23271378.
- Herd Immunity Simulator(English) written by Shane Killian and modified by Robert Webb
- GACVS; Global Expert Committee on Vaccine Safety (2015-12-17) (pdf). Statement on the safety of the HPV vaccine (tentative translation) (Report). World Health Organization 2018/4/20Browse.. Statement on Safety of HPV vaccines, 17 December 2015. The 19th MHLW Side Reactions Study GroupMaterial by
- "Collective immunity』- Koto bank